HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00102063

Two aripiprazole doses for adolescents with schizophrenia

About this titleRead the official source — NCT00102063
Medication studyAges 13–17United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.

Listed locations
Birmingham and 54 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2004
Recruitment status
Completed
Enrollment listed in the registry
302
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 13 Years to 17 Years
Official registry ID
NCT00102063
Official title
Show the full official title

Aripiprazole in Adolescents With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham, United States · Little Rock, United States · Costa Mesa, United States

51 more locations
  • Los Angeles, United States
  • National City, United States
  • Orange, United States
  • Pasadena, United States
  • Sacramento, United States
  • San Diego, United States
  • Temecula, United States
  • Washington D.C., United States
  • Altamonte Springs, United States
  • Fort Lauderdale, United States
  • Gainesville, United States
  • Hialeah, United States
  • Jacksonville, United States
  • Miami, United States
  • North Miami, United States
  • Orange City, United States
  • Tampa, United States
  • Newnan, United States
  • Smyrna, United States
  • Honolulu, United States
  • Chicago, United States
  • Kansas City, United States
  • Lexington, United States
  • Lake Charles, United States
  • New Orleans, United States
  • Medford, United States
  • Clinton Township, United States
  • Flowood, United States
  • Las Vegas, United States
  • Elmsford, United States
  • New York, United States
  • Olean, United States
  • Rochester, United States
  • Chapel Hill, United States
  • Cleveland, United States
  • Lyndhurst, United States
  • Oklahoma City, United States
  • Bala-Cynwyd, United States
  • Philadelphia, United States
  • Memphis, United States
  • Bellaire, United States
  • DeSoto, United States
  • Houston, United States
  • San Antonio, United States
  • Salt Lake City, United States
  • Richmond, United States
  • Kirkland, United States
  • Spokane, United States
  • Wauwatosa, United States
  • Rio Piedras, Puerto Rico
  • San Juan, Puerto Rico
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole tablet, 10 mg, Aripiprazole tablet, 30 mg and Placebo tablet.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies